Argyrakopoulou Georgia, Gitsi Evdoxia, Konstantinidou Sofia K, Kokkinos Alexander
Diabetes and Obesity Unit, Athens Medical Center, 15125, Athens, Greece.
First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Int J Obes (Lond). 2025 Mar;49(3):381-387. doi: 10.1038/s41366-024-01533-3. Epub 2024 May 14.
Obesity pharmacotherapy represents a promising approach to treating obesity and may provide benefits beyond weight loss alone. Maintaining or even increasing muscle mass during weight loss is important to overall health, metabolic function and weight loss maintenance. Drugs such as liraglutide, semaglutide, tirzepatide, and naltrexone/bupropion have shown significant weight loss effects, and emerging evidence suggests they may also have effects on body composition, particularly a positive influence on muscle mass. However, further research is needed to fully understand the mechanism of action of these drugs and their effects on muscle mass. Clinicians should consider these factors when developing an obesity treatment plan for an individual patient.
肥胖症药物治疗是一种很有前景的治疗肥胖症的方法,可能带来的益处不仅仅是减轻体重。在减肥过程中维持甚至增加肌肉量对整体健康、代谢功能及体重维持都很重要。利拉鲁肽、司美格鲁肽、替尔泊肽和纳曲酮/安非他酮等药物已显示出显著的减肥效果,新出现的证据表明它们可能还对身体成分有影响,尤其是对肌肉量有积极影响。然而,需要进一步研究以全面了解这些药物的作用机制及其对肌肉量的影响。临床医生在为个体患者制定肥胖症治疗方案时应考虑这些因素。